NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $0.54 -0.02 (-3.39%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.54 0.00 (-0.02%) As of 10/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rallybio Stock (NASDAQ:RLYB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rallybio alerts:Sign Up Key Stats Today's Range$0.53▼$0.5550-Day Range$0.50▼$0.6352-Week Range$0.22▼$1.24Volume102,556 shsAverage Volume342,998 shsMarket Capitalization$22.36 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingReduce Company Overview Rallybio Therapeutics, Inc. (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options. Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. Additional pipeline candidates target lysosomal storage disorders and severe skin fragility syndromes, underscoring the company’s commitment to a precision‐medicine approach. Each program has been selected based on compelling preclinical or early clinical data that suggest a clear path to regulatory milestones and commercialization. Founded in 2018 and headquartered in New York City, Rallybio completed its initial public offering via a business combination in 2021. The company leverages strategic partnerships, external research collaborations and internal manufacturing capabilities to accelerate development timelines and maintain rigorous quality standards. While Rallybio’s primary operations are based in the United States, its clinical trial network spans North America, Europe and Asia Pacific, reflecting its objective to serve rare disease communities on a global scale. Rallybio is led by a management team with extensive experience in rare disease research, drug development and regulatory strategy. The company aims to build on its scientific foundation by expanding its pipeline, advancing key assets toward commercialization and fostering collaborations that enhance access to therapies for underserved patient populations worldwide.AI Generated. May Contain Errors. Read More Rallybio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreRLYB MarketRank™: Rallybio scored higher than 56% of companies evaluated by MarketBeat, and ranked 466th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingRallybio has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialRallybio has a consensus price target of $5.00, representing about 834.4% upside from its current price of $0.54.Amount of Analyst CoverageRallybio has only been the subject of 1 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.34) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.61% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently decreased by 21.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.61% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently decreased by 21.48%, indicating that investor sentiment is improving significantly. News and Social Media1.5 / 5News SentimentN/A News SentimentRallybio has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for RLYB on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Rallybio to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLYB Stock News HeadlinesRallybio (NASDAQ:RLYB) Rating Lowered to "Sell" at Wall Street ZenOctober 12, 2025 | americanbankingnews.comRallybio (RLYB) Receives a Hold from Evercore ISIOctober 10, 2025 | theglobeandmail.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 19 at 2:00 AM | Porter & Company (Ad)Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudySeptember 25, 2025 | businesswire.comRallybio receives $12.5M equity milestone payment from Recursion PharmaceuticalsSeptember 3, 2025 | msn.comRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 ProgramSeptember 3, 2025 | finance.yahoo.comRallybio Granted Extension for Nasdaq ComplianceAugust 29, 2025 | tipranks.comTD Cowen Reaffirms Their Buy Rating on Rallybio (RLYB)August 12, 2025 | theglobeandmail.comSee More Headlines RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $0.96 at the start of the year. Since then, RLYB shares have decreased by 44.3% and is now trading at $0.5351. How were Rallybio's earnings last quarter? Rallybio Corporation (NASDAQ:RLYB) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. The business had revenue of $0.21 million for the quarter. Rallybio had a negative net margin of 5,473.33% and a negative trailing twelve-month return on equity of 71.66%. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rallybio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rallybio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Plug Power (PLUG). Company Calendar Last Earnings8/07/2025Today10/19/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Rallybio$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+834.4%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.78 million Net Margins-5,473.33% Pretax Margin-5,218.27% Return on Equity-71.66% Return on Assets-65.06% Debt Debt-to-Equity RatioN/A Current Ratio9.98 Quick Ratio9.98 Sales & Book Value Annual Sales$640 thousand Price / Sales34.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book0.36Miscellaneous Outstanding Shares41,790,000Free Float38,151,000Market Cap$22.36 million OptionableNot Optionable Beta-1.10 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RLYB) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.